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This study aims to evaluate outcomes associated with different P2Y12 agents in Saphenous Vein graft (SVG) percutaneous coronary intervention (PCI). 
Background
SVG PCI is associated with greater risks of ischemic complications, compared to native coronary PCI. Outcomes associated with the use of potent P2Y12 blocking drugs, Prasugrel and Ticagrelor, in SVG PCI are unknown.  
Methods
Patients included in the study underwent SVG PCI in the United Kingdom between 2007-2014 for acute coronary syndrome and were grouped by P2Y12 antiplatelet use. In-hospital major adverse cardiac events, major bleeding and 30-day and 1-year mortality were examined. Multiple imputations with chained equations to impute missing data were used. Adjustment for baseline imbalances was performed using i) multiple logistic regression (MLR) and (separately) ii) propensity score matching (PSM). 
Results








Percutaneous coronary intervention (PCI) to saphenous vein grafts (SVG) is associated with increased risks, both acutely (particularly no-reflow) and longer-term vessel failure, compared to native coronary intervention.[1] These relate to differences in pathology – beyond the first year after bypass surgery, the predominant mechanism of SVG stenosis is atherosclerotic but characterized by more diffuse disease, greater foam cell and inflammatory cell components and less well-developed fibrous caps than in native coronary disease.[2] Such features render SVG lesions more prone to distal embolization during PCI and, in acute presentations, more often associated with a heavy thrombus burden.[3] SVG intervention represents an important component of the recent DAPT score for predicting future ischemic risk.[4] Hence peri-procedural myocardial ischemia and infarction are major concerns, notwithstanding use of strategies to reduce these, such as embolic protection devices[5,6] and/or vasoactive drugs.[7]
The role of potent platelet inhibition in ameliorating these problems is not clear. For example, intravenous glycoprotein IIb/IIIa inhibitor (GPI) use has not been associated with same benefits in SVG PCI as seen in native coronary intervention,[8] except possibly when used in conjunction with embolic protection.[9] More recently, the potent selective P2Y12 agents, Ticagrelor and Prasugrel, have become available and show a reduction in ischemic endpoints following PCI for acute coronary syndromes (ACS), compared to Clopidogrel.[10,11] There was also a reduction in all-cause mortality with Ticagrelor in this setting. This has led to increasing use of these agents in PCI settings associated with higher ischemic risk. Outside their role in PCI, potent P2Y12 blockade is also seen to improve graft patency following coronary artery bypass graft (CABG) surgery.[12]  However, there are little data regarding possible benefits of potent P2Y12 inhibitor use in the specific setting of SVG PCI for ACS. The data cited above in relation to GPIs caution against extrapolation from non-SVG studies. In the PLATO study, the outcomes in post-CABG patients with Ticagrelor use did not appear to differ from the overall study findings[13] – however this was a post-hoc analysis in which the usual caveats regarding potentially unbalanced comparison groups apply. Additionally, outcomes in that paper were not separated based on whether PCI was undertaken in a bypass graft or native vessel, further limiting interpretation. No equivalent subgroup evaluation is available for Prasugrel from TRITON-TIMI 38. 




Study design and data collection
	The BCIS database records information on PCI procedures in the UK and the data collection is managed by the National Institute of Cardiovascular Outcomes Research (NICOR).[14,15,16] A retrospective analysis was performed of all participants with PCI to vein grafts and receipt of dual antiplatelet therapy from England and Wales between January 2007 and December 2014. Participants were tracked via the patient's National Health Service (NHS) number, a unique identifier for any person registered within the NHS in England and Wales, for mortality and adverse in-hospital outcomes. 

Variables, exposures and outcomes
	Data on participants' demographics (age, sex, body mass index and smoking status) and comorbidities (diabetes, hypertension, hypercholesterolemia, previous myocardial infarction, previous stroke, peripheral vascular disease, renal disease, valvular heart disease) were collected.  Additional information was collected on previous CABG, previous PCI, radial access, cardiogenic shock, circulatory support, receipt of ventilation, diagnosis, glycoprotein IIb/IIIa inhibitor use, warfarin, thrombolysis, embolic protection device, PCI to non-vein graft vessel, use of drug eluting stent and year of PCI procedure.  The primary exposure variable was Clopidogrel, Prasugrel and Ticagrelor and the outcome variables were 30-day and 1 year mortality, and in-hospital major adverse cardiovascular events (defined by in-hospital death, in-hospital Non-Q wave and Q wave myocardial infarction, re-infarction, emergency CABG and re-intervention PCI). 
Statistical methods





Figure 1 displays the numbers of cases eligible for analysis during the study period and reasons for case exclusion. A total of 8,119 patients comprised our main study cohort.  Their baseline clinical data, year of PCI procedure, details of adjunctive therapy and unadjusted clinical outcomes are shown in Table 1, grouped by the P2Y12 antiplatelet agent used. The cohort that was treated with Clopidogrel (n=7,401) was numerically much larger than either the cohort that was treated with Ticagrelor (n=497) or Prasugrel (n=221). Clopidogrel use in SVG PCI was seen to decline after 2010, as demonstrated graphically in Figure 2. Over this time, there has been an increase in Ticagrelor use year-on-year, whilst Prasugrel use in this setting has remained stable since 2011. 
Despite the marked difference in overall group sizes, the mean age and gender distribution was similar across groups. It is noteworthy that patient age range, body mass index and the frequency of previous CVA were similar between the different P2Y12 groups.  
Some important differences between the characteristics of the groups also merit specific mention. The predominant use of Prasugel was in the setting of STEMI whilst for Ticagrelor, use in NSTEMI/UA was most frequent. There was a higher proportion of radial access use in the patients receiving more potent P2Y12 blockers, which might be a time (i.e. year of treatment)-dependent effect. Greater use of embolic protection devices was seen with Ticagrelor, whilst use of adjunctive GPI was highest with Prasugrel. Table 2, showing predictors of P2Y12 antiplatelet choice from multivariable analysis, indicates those which appear to be independently associated with their use. Whilst younger age appears as a predictor for both Prasugrel and Ticagrelor use, the odds ratio of around 1 indicates a very small effect size, as seen from the raw data in Figure 1.   




Vein graft PCI represents a distinct subset, for which patient outcomes remain inferior to those seen in native coronary disease. Hence a search for approaches to improve outcomes for patients with vein graft disease is important. Where practical, treatment of native disease in the territory of the diseased graft (rather than the graft itself) is now the preferred option. However, this is not always straightforward, particularly if this native coronary contains a complex chronic total occlusion or has diffuse severe disease. So SVG PCI will continue to be the favoured revascularization option in a proportion of cases, and therefore defining an optimal anti-ischemic strategy in such cases remains important. There is currently a lack of trial evidence or observational data on the effect of potent specific P2Y12 receptor inhibition in SVG PCI. 

Key findings of this work and possible explanations
SVG PCI represented a small proportion (approximately 2%) of overall PCI activity within the UK and the majority of such cases were undertaken in the setting of ACS with use of potent P2Y12 blockade (with Prasugrel or Ticagrelor) predominantly in such ACS cases. One unanticipated finding from our work was noted in relation to the demographics of patients receiving Prasugrel. In TRITON TIMI 38, subgroup analyses indicated worse outcomes in Prasugrel-treated patients with previous CVA, and neutral findings in those of age>75 years or with body weight <60kg, leading to specific precautions for these cohorts in the marketing authorization.[19] Nevertheless, in real-world practice, the Prasugrel group appeared similar with respect to these clinical variables to the other groups. One can only speculate as to the reasons involved but the high proportion of STEMI cases in the Prasugrel group might have led to clinical decisions prioritizing rapidity of onset of action with Prasugrel (in this most acute of settings) above the known increased bleeding risks. 
The changing pattern of antiplatelet use for SVG PCI over the study period is noteworthy.  The increasing use of more potent P2Y12 agents is likely explained by an extrapolation of favourable findings from landmark trials in ACS, in the absence of any direct positive or negative data for the specific context of SVG intervention. More interesting however is the fairly stable pattern of Prasugrel uptake, in contrast to the steadily increasing use of Ticagrelor. Possible influencing factors here include more favourable evidence with Ticagrelor in terms of all-cause mortality reduction, and its apparent advantages over Prasugrel in specific settings such as medically managed ACS[10,13,20] and in specific groups such as the elderly.[21] These considerations might have influenced individual institutions’ decisions in opting to switch to one or other P2Y12 blocker in high-risk ACS, and hence also (as a consequence) in the SVG PCI subset of these patients.   
	We observed higher use of radial access and of embolic protection devices with potent P2Y12 blockers that may have favoured better outcomes with these agents in unadjusted analyses, although this effect was mitigated in the adjusted analyses once differences in baseline covariates were made. The markedly higher use of GPI seen with Prasugrel likely reflected the high proportion of STEMI cases in that group, where onset of antiplatelet action is most rapidly required. As noted earlier, the benefit of GPI in the setting of SVG PCI is equivocal (although its adverse impact on risk of bleeding is not).     
Following multivariable analysis, we observed no significant differences for the potent P2Y12 blockers over Clopidogrel in SVG PCI for a number of clinically important endpoints. There are various potential explanations for this finding. Firstly, the pathophysiology of vein graft disease may lead to downstream debris during PCI that differs significantly in composition from that encountered with native coronary atheroma. Friable, foam-cell rich plaque might constitute the bulk of such debris and this could explain the lack of effect seen with both GPI and (in our present work) with potent oral P2Y12 blockers. 
A second possibility is that a benefit with Ticagrelor or Prasugrel over Clopidogrel might actually exist but our study was underpowered to detect this, given i) the relatively low patient numbers in the potent P2Y12 groups and ii) the modest event rates across all groups. This possibility is difficult to exclude fully and would require significantly larger numbers to clarify, although it is unlikely that an adequately powered randomised trial would ever be undertaken to investigate this. Furthermore, any clinical benefit with potent P2Y12 agents in SVG PCI may not be sufficient to be seen as a survival advantage but might produce a reduction in recurrent myocardial infarction or MACE. Such an effect would not be detected outside the index hospital admission in our present work. A third possibility for our present findings is that an anti-ischemic benefit exists with potent P2Y12 blockers but that any mortality benefit is offset by adverse effects from later (post-discharge) major bleeding. This is plausible, given the demographics of the potent P2Y12 groups, which contain subgroups known to be at higher risk of bleeding problems. Clarification of this issue would require more information about cause of death, and capture of ischemic and bleeding events post discharge which is not currently available in the BCIS dataset.

Limitations 
There are certain limitations in this work that apply to all observational and registry-based research. Most importantly, such studies cannot determine cause and effect and hence only associations can be identified. Additionally, conclusions drawn from these associations may be influenced by confounders that will not be ‘visible’ on the dataset (unmeasured confounding). These reflect variables which are not captured but which are related to both (non-blinded) treatment allocation and to outcome. Among these are factors such as frailty and non-cardiovascular co-morbidity.[22,23] However, in this particular work, clinical assessment of frailty or multi-morbidity would be expected to lead to use of Ticagrelor or Prasugrel in ‘less frail’ / multi-morbid patients overall, and hence any confounding in this regard should favour outcomes in the potent P2Y12 groups. Hence, it is unlikely that neutral effects on outcome found with these agents in our study are attributable to being disadvantaged by frailty as an unrecorded confounder.  In addition, we did not have information on the age of the graft at time of PCI.   While our analysis suggests no difference in outcomes for patients depending on choice of antiplatelet therapy, there may still be a difference depending on treatment but we are not able to detect it in the current study due to small sample size.

Another recognized limitation is that robust outcome tracking is currently available only for mortality. Clinical advantages with more potent antiplatelet agents may exist but may not be sufficient to appear as a mortality signal. In-hospital MACE and bleeding rates were available but a reliance on retrospective documentation at a centre-level (rather than by robust linkage) is likely to contribute to low recorded event rates for these endpoints. Furthermore, out of hospital MACE and bleeding events are not captured on our dataset, unless fatal. Nevertheless despite such limitations, our study provides important new data around outcomes associated with newer P2Y12 agents in SVG PCI as there is unlikely to be an adequately powered RCT comparing outcomes for hard clinical endpoints and so should be considered best available evidence currently available. 

Conclusions
Our study of real world SVG PCI from the UK national registry shows no benefit in  30-day mortality, 1-year mortality or in-hospital complications for the newer, more potent, oral P2Y12 antiplatelet agents over Clopidogrel. 
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Table 1: Participant characteristics
Variable	Clopidogrel (n=7,401)	Prasugrel (n=221)	Prasugrel vs clopidogrel p-value	Ticagrelor (n=497)	Ticagrelor vs clopidogrel p-value
Age	71±9	69±9	<0.001	70±9	0.13
Male sex	6,221 (84%)	189 (86%)	0.60	420 (85%)	0.71
Body mass index	28±5	29±4	0.21	29±5	0.077
Current or ex- smoker	730 (11%)	38 (19%)	<0.001	66 (14%)	0.048
Diabetes 	2,513 (35%)	65 (30%)	0.12	190 (39%)	0.10
Hypertension	5,230 (73%)	150 (72%)	0.71	355 (75%)	0.40
Hypercholesterolemia	5,307 (74%)	152 (73%)	0.60	315 (67%)	<0.001
Previous myocardial infarction	4,960 (74%)	162 (76%)	0.51	318 (71%)	0.31
Previous stroke	597 (8%)	13 (6%)	0.28	40 (9%)	0.92
Peripheral vascular disease	929 (13%)	23 (11%)	0.41	59 (13%)	0.77
Renal disease	143 (2%)	4 (2%)	0.90	1 (0.2%)	0.005
Valvular heart disease	202 (3%)	5 (2%)	0.72	13 (3%)	0.92
Previous PCI	2,959 (41%)	100 (46%)	0.12	186 (38%)	0.20
Radial access	1,578 (22%)	64 (29%)	0.007	204 (42%)	<0.001
Cardiogenic shock	138 (2%)	8 (4%)	0.071	12 (2%)	0.43
Circulatory support	158 (2%)	12 (6%)	0.001	6 (1%)	0.17
Receipt of ventilation	83 (1%)	4 (2%)	0.40	11 (2%)	0.036
DiagnosisNSTEMI/UASTEMI	6,151 (88%)809 (12%)	68 (32%)146 (68%)	<0.001	371 (76%)118 (24%)	<0.001
Glyoprotein IIb/IIIa inhibitor (GPI) use	2,043 (30%)	93 (45%)	<0.001	123 (27%)	0.20
Warfarin	121 (2%)	2 (0.9%)	0.32	4 (0.8%)	0.097
Thrombolysis	163 (3%)	3 (2%)	0.35	1 (0.3%)	0.005
Embolic protection device	1,397 (20%)	31 (15%)	0.052	109 (23%)	0.090
Non-graft PCI	1,232 (17%)	34 (15%)	0.62	60 (12%)	0.008
Drug eluting stent	4,810 (65%)	155 (70%)	0.11	417 (84%)	<0.001
Year20072008200920102011201220132014	785 (11%)974 (13%)1,095 (15%)1,139 (15%)966 (13%)941 (13%)835 (11%)666 (9%)	0 (0%)1 (0.5%)2 (0.9%)22 (10%)53 (24%)56 (25%)46 (21%)41 (19%)	<0.001	0 (0%)0 (0%)0 (0%)
1 (0.2%)2 (0.4%)61 (12%)171 (34%)262 (53%)	<0.001
Mortality at 30 days	207 (3%)	13 (6%)	0.007	8 (2%)	0.12
Mortality at 1 year	581 (9%)	23 (13%)	0.052	16 (7%)	0.33
In-hospital MACE	176 (2%)	8 (4%)	0.24	12 (2%)	0.97
In-hospital bleeding	37 (0.5%)	1 (0.5%)	0.92	2 (0.4%)	0.76




Table 2: Multivariable predictors of antiplatelet use 
A) Significant multivariable predictors of prasugrel use





Diagnosis compared to NSTEMI/UASTEMI	14.81 (10.55-20.77)	<0.001
NSTEMI=non-ST segment elevated myocardial infarction, UA=unstable angina, STEMI=ST-elevated myocardial infarction

B) Significant multivariable predictors of ticagrelor use





Diagnosis compared to NSTEMI/UASTEMI	2.12 (1.60-2.82)	<0.001
Embolic protection device	1.50 (1.15-1.96)	0.003
Drug eluting stent	1.64 (1.24-2.16)	<0.001




Table 3: Odds of adverse outcome
Analysis	n	Odds ratio (95% CI)	p-value
Multivariable 30 day mortality compared to ClopidogrelPrasugrelTicagrelor	7,930	1.22 (0.60-2.51)0.48 (0.20-1.16)	0.580.10
Multivariable 1 year mortality compared to ClopidogrelPrasugrelTicagrelor	6,979	1.36 (0.81-2.28)0.71 (0.39-1.30)	0.240.27
Multivariable in-hospital MACE compared to ClopidogrelPrasugrelTicagrelor	7,867	0.64 (0.27-1.50)0.95 (0.45-2.01)	0.31 0.90
Multivariable in-hospital bleeding compared to Clopidogrel*PrasugrelTicagrelor	7,756	0.47 (0.05-4.06)1.04 (0.21-5.07)	0.490.96





Table 4: Propensity score match analysis with average treatment effects
Analysis	Group	Coefficient	95% CI	p-value
30 day mortality	Prasugrel vs Clopidogrel (n=7,444)	0.0430 	-0.0354	0.1214	0.28
	Ticagrelor vs Clopidogrel (n=7,713)	-0.0099	-0.0376	0.0179	0.48
	Ticagrelor vs Prasugrel (n=703)	-0.0326 	-0.0935	0.0283	0.28
1 year mortality	Prasugrel vs Clopidogrel (n=6,749)	0.1254 	-0.0684	0.3192	0.20
	Ticagrelor vs Clopidogrel  (n=6,803)	-0.0179	-0.0779	0.0421	0.56
	Ticagrelor vs Prasugrel (n=406)	-0.0741	-0.1489	0.0006	0.052
In-hospital MACE	Prasugrel vs Clopidogrel (n=7,383)	0.0002	-0.0394	0.398	0.99
	Ticagrelor vs Clopidogrel (n=7,652)	-0.0083	-0.0245	0.0079	0.31
	Ticagrelor vs Prasugrel (n=699)	0.0040	-0.0251	0.0331	0.79
In-hospital bleeding	Prasugrel vs Clopidogrel (n=7,381)	0.0132	-0.0246	0.0511	0.49
	Ticagrelor vs Clopidogrel (n=7,650)	0.0004	-0.0085	0.0094	0.93
	Ticagrelor vs Prasugrel (n=699)	-0.0016	-0.0168	0.0137	0.84












































Supplementary Table 2: Matching success diagnostics for propensity model

Comparison	Group	Mean (SD)	Median (IQR)
Prasugrel vs Clopidogrel 	Case	0.9708 (0.0555)	0.9900 (0.9814-0.9937)
	Control	0.9708 (0.0554)	0.9897 (0.9814-0.9937)
	Abs(Case-Control)	0.0003 (0.0008)	0.00014 (0.00005-0.00030)
Ticagrelor vs Clopidogrel 	Case	0.9370 (0.0561)	0.9231 (0.9528-0.9740)
	Control	0.9369 (0.0560)	0.9527 (0.9231-0.9745)
	Abs(Case-Control)	0.0003 (0.0012)	0.00013 (0.00004-0.00030)
Ticagrelor vs Prasugrel	Case	0.3087 (0.2263)	0.2065 (0.1221-0.5056)
	Control	0.3076 (0.2233)	0.2077 (0.1224-0.5055)
	Abs(Case-Control)	0.0031 (0.0107)	0.0011 (0.0004-0.0025)





